Full-Time

Quality Control Lab Technician I

Posted on 10/4/2025

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

No salary listed

Westborough, MA, USA

In Person

Category
QA & Testing (1)
Requirements
  • High school diploma or general education degree (GED)
  • Minimum 0-1 years’ relevant experience in a pharmaceutical testing laboratory
Responsibilities
  • Perform microbiological testing (endotoxin, bioburden) for water
  • Perform microbiological testing (endotoxin, sterility and bioburden) for raw materials, in-process materials, intermediates and final product
  • Perform environmental monitoring of the clean rooms (under USP and EU specifications)
  • Review documentation, analytical chromatographic data and results from instrumental testing such as DSC, XRPD, water analysis, USP testing, etc. for compliance with cGMPs, Curia SOPs and other written procedures
  • Analyze data for stability trends and deviations to ensure consistency with historical time points and prevent unexpected results
  • Manage timelines and multiple projects by Interfacing with scientists and management to coordinate testing timelines, corrections to documentation, and reporting within defined turnaround times. Adjust priorities based on due dates and invoicing goals
  • Assist in writing stability protocols
  • Interact with outside testing laboratories to coordinate shipment and testing of stability samples
  • Develop direct, technical communication with primarily external customers to report results, engage in technical discussion and address questions
  • Review and format reports such as Stability Summary tables to ensure accuracy and compliance with current Curia formats
  • Manage invoicing for stability, which includes issuing BRFs, working with finance to ensure accurate and complete accounting for stability projects, reviewing monthly invoices and tracking monthly and quarterly financial projections
  • Handle controlled substances including maintaining inventory, completing paperwork, and conducting biannual review
  • Manage workload and time to enable the incumbent to perform multiple projects effectively and ensure all necessary paperwork is completed on a timely basis
  • Volunteer to assist with other tasks in the analytical function not directly related to specific projects
  • Participate in self-development activities and training others
  • Write proposals and design studies for stability

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$1.1B

Headquarters

Albany, New York

Founded

1991

Simplify Jobs

Simplify's Take

What believers are saying

  • Biologics segment expansion under Steve Lavezoli accelerates high-margin pharmaceutical outsourcing revenue growth.
  • Carterra partnership positions Curia to capture Pacific Northwest biotech demand in antibody discovery services.
  • Gerald Auer's CFO appointment signals M&A activity and potential strategic initiatives enhancing shareholder value.

What critics are saying

  • Pace Life Sciences acquisition of New Jersey lab erodes Curia's analytical testing capacity and revenue.
  • Larger CDMOs like Lonza and Catalent undercut Curia on biologics capacity, stealing biotech contracts.
  • FDA scrutiny on srRNA manufacturing defects from Replicate Bioscience Phase 1 triggers potential client exodus.

What makes Curia unique

  • Pioneer in self-replicating RNA manufacturing, demonstrated through Replicate Bioscience Phase 1 clinical trial support.
  • Integrated enzymatic doggybone DNA technology via Touchlight collaboration expands mRNA manufacturing competitive advantages.
  • End-to-end CDMO services from discovery through cGMP manufacturing differentiate Curia from specialized competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Carlyle Group
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb.com
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

PPI News Agency
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.

INACTIVE